Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.

Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A.

Clin Pharmacol Ther. 2009 Oct;86(4):396-402. doi: 10.1038/clpt.2009.139. Epub 2009 Jul 22.

2.

Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.

Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jürgens H, Schlatter E.

Am J Pathol. 2010 Mar;176(3):1169-80. doi: 10.2353/ajpath.2010.090610. Epub 2010 Jan 28.

3.

Cisplatin-induced renal injury is independently mediated by OCT2 and p53.

Sprowl JA, Lancaster CS, Pabla N, Hermann E, Kosloske AM, Gibson AA, Li L, Zeeh D, Schlatter E, Janke LJ, Ciarimboli G, Sparreboom A.

Clin Cancer Res. 2014 Aug 1;20(15):4026-35. doi: 10.1158/1078-0432.CCR-14-0319. Epub 2014 Jun 10.

4.

Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.

Franke RM, Kosloske AM, Lancaster CS, Filipski KK, Hu C, Zolk O, Mathijssen RH, Sparreboom A.

Clin Cancer Res. 2010 Aug 15;16(16):4198-206. doi: 10.1158/1078-0432.CCR-10-0949. Epub 2010 Jul 2.

5.
6.

Interaction of Cisplatin with the human organic cation transporter 2.

Filipski KK, Loos WJ, Verweij J, Sparreboom A.

Clin Cancer Res. 2008 Jun 15;14(12):3875-80. doi: 10.1158/1078-0432.CCR-07-4793.

7.

[Platinum agent-induced nephrotoxicity via organic cation transport system].

Yonezawa A.

Yakugaku Zasshi. 2012;132(11):1281-5. Review. Japanese.

8.

Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.

Iwata K, Aizawa K, Kamitsu S, Jingami S, Fukunaga E, Yoshida M, Yoshimura M, Hamada A, Saito H.

Clin Exp Nephrol. 2012 Dec;16(6):843-51. doi: 10.1007/s10157-012-0638-y. Epub 2012 May 9.

PMID:
22569819
9.

Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).

Li Q, Guo D, Dong Z, Zhang W, Zhang L, Huang SM, Polli JE, Shu Y.

Toxicol Appl Pharmacol. 2013 Nov 15;273(1):100-9. doi: 10.1016/j.taap.2013.08.024. Epub 2013 Aug 31.

10.

Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.

Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstädt H, Massmann V, Guckel D, Mathijssen RH, Yang W, Pui CH, Relling MV, Herrmann E, Sparreboom A.

Clin Cancer Res. 2012 Feb 15;18(4):1101-8. doi: 10.1158/1078-0432.CCR-11-2503. Epub 2012 Jan 5.

11.

Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice.

Oda M, Koyanagi S, Tsurudome Y, Kanemitsu T, Matsunaga N, Ohdo S.

Mol Pharmacol. 2014 May;85(5):715-22. doi: 10.1124/mol.113.089805. Epub 2014 Feb 24.

12.

Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.

Komazawa H, Yamaguchi H, Hidaka K, Ogura J, Kobayashi M, Iseki K.

J Pharm Sci. 2013 Mar;102(3):1086-94. doi: 10.1002/jps.23433. Epub 2012 Dec 29.

PMID:
23280877
13.

Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2.

Tanihara Y, Masuda S, Katsura T, Inui K.

Biochem Pharmacol. 2009 Nov 1;78(9):1263-71. doi: 10.1016/j.bcp.2009.06.014. Epub 2009 Jun 18.

PMID:
19540211
15.
16.

Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake.

Choi MK, Song IS.

Biopharm Drug Dispos. 2012 Apr;33(3):170-8. doi: 10.1002/bdd.1783. Epub 2012 Mar 17.

PMID:
22415520
17.

Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity.

Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K.

Biochem Pharmacol. 2010 Dec 1;80(11):1762-7. doi: 10.1016/j.bcp.2010.08.019. Epub 2010 Sep 9.

PMID:
20813096
18.

Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients.

Jung N, Lehmann C, Rubbert A, Schömig E, Fätkenheuer G, Hartmann P, Taubert D.

Infection. 2013 Apr;41(2):379-85. doi: 10.1007/s15010-012-0308-8. Epub 2012 Aug 9.

PMID:
22875535
19.

Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.

Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K.

Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.

20.

Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.

Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11199-204. doi: 10.1073/pnas.1305321110. Epub 2013 Jun 17.

Supplemental Content

Support Center